Kurzfassung

A 12 week double-blind, randomised, placebo-controlled, modified doseescalation
trial to investigate safety, efficacy, and pharmacokinetics of BIRT
2584XX tablets at doses of 100, 300 and 500 mg administered once daily in
patients with moderate to severe psoriasis with a 12 week treatment
extension for PASI 50 responders